As the Trump administration begins to make its mark on the Medicare drug price negotiation program and pursue its own policies on prescription drugs, litigation over program continues. In the two ...
A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ challenges to the Inflation Reduction Act of 2022's (IRA) Medicare Drug ...
On May 12, 2025, the Centers for Medicare & Medicaid Services (CMS) issued draft guidance for the third cycle of the IRA’s Medicare Drug Price Negotiation Program (Negotiation Program). This draft ...
Three federal courts reject legal challenges to Medicare drug price negotiation Judges side with government in cases filed by Boehringer Ingelheim, PhRMA, and the U.S. Chamber of Commerce Rulings ...
Drugmaker Merck & Co. filed a lawsuit Tuesday alleging President Biden's marquee effort to negotiate down the cost of drugs under Medicare is "tantamount to extortion" and violates the Constitution.
An appeals court has ruled against a legal challenge to the Drug Price Negotiation Program. On Wednesday, the U.S. Court of Appeals for the Sixth Circuit sided with the Department of Health and Human ...
As President Donald Trump touts new deals to cut the cost of blockbuster drugs like Wegovy and Zepbound, he’s barely mentioned Medicare’s drug price negotiation program — even though the government is ...
CMS proposed several changes for the third round of Medicare drug price negotiations, including the potential inclusion of some drugs under Medicare Part B, in a draft guidance published May 12. The ...
Recently approved delays and exemptions to the CMS drug price negotiation program are projected to cost $8.8 billion over 10 years, according to a Congressional Budget Office report published Oct. 20.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback